|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In the discovery series cohort, we found a 4-loci interaction involving STK11 rs8111699, FCHSD1 rs456998, GSK3B rs1732170, and SNCA rs356219, which was associated with an increased risk of PD (odds ratio = 2.59, P < .001).
|
31234232 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glycogen synthase kinase 3β (GSK-3β) and casein kinase 1δ (CK-1δ) are emerging targets for the treatment of neuroinflammatory disorders, including Parkinson's disease.
|
30548443 |
2019 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-2 and GSK3B proteins are T and natural killer (NK) cell regulators and have previously been associated with other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and multiple system atrophy.
|
31123295 |
2019 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models.
|
31325476 |
2019 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Graphical Abstract In the rat rotenone model of Parkinson's disease (PD), Nurr1 expression was downregulated, GSK-3β was activated, and autophagic flux was inhibited.
|
29429051 |
2018 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
GSK-3β inhibition enhances dendritic arborization and survival of granular neurons and stimulates NSC differentiation towards the neuronal phenotype in DG of PD model.
|
29327199 |
2018 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Consistently, significant decrease in IRβ, IRS1, PI3K p85, Akt1/2/3 and PIP3 levels and increased GSK3β level were observed in TH obtained from SN region of PD brain compared to the control brain.
|
29288045 |
2018 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Thus, our study demonstrates that P7C3 protects DA neurons from neurotoxin-induced cell death by repressing the GSK3β-p53-Bax pathway both in vitro and in vivo, thus providing a theoretical basis for P7C3 in the potential clinical treatment of PD.
|
28569794 |
2017 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Therefore, the intriguing ability of several anesthetics to readily inhibit GSK3β within the cortex and hippocampus led us to investigate the effects of brief isoflurane anesthesia on striatal GSK3β signaling in naïve rats and in a rat model of early-stage PD.
|
28488766 |
2017 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
MK-801 inhibited glycogen synthase kinase-3β (GSK-3β) through up-regulation of Wnt-3a, which resulted in the activation of Wnt/β-catenin signaling leading to enhanced hippocampal neurogenesis in PD model.
|
27977132 |
2017 |
|
Parkinson Disease
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Accumulative evidence demonstrates that GSK-3β inactivation may be potentially developed as the promising strategy in management of many diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29190615 |
2017 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Findings were further validated by expression analyses of a target gene GSK3B, known to be affected by AD and PD.
|
27853238 |
2016 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Although several kinases are known to phosphorylate α-Syn and Tau, we focused our analysis on GSK-3β because of its accepted role in phosphorylating Tau and to increasing evidence supporting a strong biophysical relationship between α-Syn and Tau in PD.
|
25394490 |
2015 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
However, the underlying mechanisms of the protective effect of GSK-3β inhibition on dopaminergic neurons in PD is not completely understood.
|
24681994 |
2014 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The GG genotype of rs242562 displays protection against PD in subgroup with GSK3B rs334558 T carrier.
|
24779391 |
2014 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
Levels were correlated with demographic and clinical variables, cerebrospinal fluid Abeta1-42, total tau and phospho-tau levels, as well as with single nucleotide polymorphisms (SNPs) of genes which either have been reported to influence the immune system, the amyloid cascade or the occurrence of PD (ApoE, GSK3B, HLA-DRA, HSPA5, SNCA, and STK39).
|
24586351 |
2014 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The association between glycogen synthase kinase 3 beta polymorphisms and Parkinson's disease susceptibility: a meta-analysis.
|
23628795 |
2013 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that rs334558 variant in GSK3β reduces the risk of PD in a Han Chinese population from mainland China.
|
22815195 |
2012 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To determine their potential role in the pathogenesis of Parkinson's disease (PD) we analyzed 2 functional single nucleotide polymorphisms (SNPs) of GSK3B (rs334558 and rs6438552) and rs735555 of CDK5 regulatory subunit 1 (CDK5R1) in 373 PD cases and 346 healthy controls of eastern India.
|
21130530 |
2012 |
|
Parkinson Disease
|
0.300 |
Therapeutic
|
disease |
RGD |
Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway.
|
23094836 |
2012 |
|
Parkinson Disease
|
0.300 |
Biomarker
|
disease |
BEFREE |
In the current study, we attempt to validate previously published findings, evaluating gene-gene interactions between SNCA, MAPT, and GSK3B in association with PD.
|
21159074 |
2011 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The C/C genotype of the rs334558 GSK3β polymorphism was also found to have an additional protective role in our MAPT H1/H1 PD subgroup.
|
19573950 |
2011 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease.
|
16315267 |
2005 |
|
Parkinson Disease
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease.
|
16315267 |
2005 |